Trial Profile
Open Label, Two Cohort (With and Without Imiglucerase), Multicenter Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Eliglustat in Pediatric Patients With Gaucher Disease Type 1 and Type 3
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs Eliglustat (Primary) ; Imiglucerase (Primary)
- Indications Gaucher's disease type I; Gaucher's disease type III
- Focus Adverse reactions; Pharmacokinetics; Registrational
- Acronyms ELIKIDS
- Sponsors Sanofi; Sanofi Genzyme
- 12 Mar 2023 This study has been completed in Sweden, According to European Clinical Trials Database.
- 12 Mar 2023 This study has been completed in Sweden, According to European Clinical Trials Database.
- 12 Aug 2022 Planned End Date changed from 1 Nov 2025 to 20 Nov 2025.